key: cord-0836677-qbi5998f authors: Behbahani, Mandana title: In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein date: 2020-03-10 journal: bioRxiv DOI: 10.1101/2020.03.10.985499 sha: 82468c289eb562a3e63d084238c08f62e617eb64 doc_id: 836677 cord_uid: qbi5998f It is of special significance to find a safe and effective vaccine against coronavirus disease 2019 (COVID-19) that can induce T cell and B cell -mediated immune responses. There is currently no vaccine to prevent COVID-19. In this project, a novel multi-epitope vaccine for COVID-19 virus based on surface glycoprotein was designed through application of bioinformatics methods. At the first, seventeen potent linear B-cell and T-cell binding epitopes from surface glycoprotein were predicted in silico, then the epitopes were joined together via different linkers. The ability of the selected epitopes to induce interferon-gamma was evaluate using IFNepitope web server. One final vaccine was constructed which composed of 398 amino acids and attached to 50S ribosomal protein L7/L12 as adjuvant. Physicochemical properties, as well as antigenicity in the proposed vaccines, were checked for defining the vaccine stability and its ability to induce cell-mediated immune responses. Three-dimensional structure of the mentioned vaccine was subjected to the molecular docking studies with MHC-I and MHC-II molecules. The results proposed that the multi-epitope vaccine with 50S ribosomal protein L7/L12 was a stable construct with high aliphatic content and high antigenicity. In early 2020, COVID-19 began generating headlines all over the world because of the extraordinary speed 28 of its transmission. So, there are rising concerns about community infections. Vaccination is one of the 29 most effective tools to prevent infectious diseases [1] [2]. As far as our knowledge concerns, there is no 30 report about developing COVID-19 multi epitope vaccine. Therefore, we became eager to design potent 31 multiepitope vaccines from antigenic sites of coronavirus surface glycoprotein. The multiepitope 32 vaccines have advantageous over conventional vaccines with regards to safety profile and high 33 immunogenicity [3] . Multiepitope vaccines have the potential to induce responses restricted by a 34 wide variety of HLA molecules and generate a balanced CD4+ and CD8+ cellular immune 35 response. Another molecule that contribute to innate immunity contains TLR3 that activates Escherichia coli [7] , Vibrio cholera [8], Human immunodeficiency virus-1 [9], Hepatitis C virus 43 [10] and many others. In several experimental studies, the efficacy of computationally designed 44 vaccines has been recently approved for use in defined human vaccines [11] [13] . In this study, in 45 silico analysis were performed to determine exclusive B cell and T-cell epitopes from coronavirus 46 surface glycoprotein that are antigenically most significant for coronavirus. In our research, some 47 unique exclusive B cell and T-cell epitopes from coronavirus surface glycoprotein were selected 48 based on their antigenicity, stability and length. The selected epitopes were merged into each other 49 using suitable linkers for organization of final vaccine construct. Consequently, the stability and 50 efficacy of the vaccines were predicted by a set of bioinformatics methods. the conserved sequence and antigenic peptide were selected for further analysis. The copyright holder for this preprint (which was not peer-reviewed) is the . Seventeen suitable common B-cell and T-cell epitopes (9-16 amino acids) from coronavirus surface 79 glycoprotein were selected and organized in the final vaccine construct. Then, these epitopes were merged 80 together with AAY, KK linkers and considered as a multi-epitope vaccine. One adjuvant "50S ribosomal 81 protein L7/L12 82 (MSDINKLAETLVNLKIVEVNDLAKILKEKYGLDPSANLAIPSLPKAEILDKSKEKTSFDLILKGAG 83 SAKLTVVKRIKDLIGLGLKESKDLVDNVPKHLKKGLSKEEAESLKKQLEEVGAEVELK) with 124 amino acids were incorporated with EAAAK linker at N-terminal portion of the constructs. 85 The sequence of the designed vaccine structures with their adjuvant are depicted in Table 3 VaxiJen score of the protein showed high antigenicity. Due to having good antigenicity, high exposure 132 probability to the immune system and high conservancy, this protein was selected for vaccine design. In the current study, some appropriate common B-cell and T-cell epitopes were designed. The predicted 135 MHC-I and MHC-II restricted epitopes were compared to B-cell epitopes to determine shared epitopes 136 (Table 2) . Finally, 17 epitopes with 9-16 amino acids were selected. These epitopes are located between 137 residues 14-642. These epitopes exhibited a relatively high aliphatic index (>60), high antigenicity (>1.6) 138 and low instability index (less than 20). The most potent epitope was repeated three times and merged 139 into the other epitopes using suitable linkers (KK, AYY) for organization of final vaccine construct. Final construct vaccine was composed of 398 amino acids which were respectively attached to 50S 142 ribosomal protein L7/L12 as adjuvant. The antigenicity score of constructed vaccine are shown in 143 Table 3 . The result demonstrated that IV1 has 1.2110 antigenicity (Table 3) . Physicochemical properties of the constructed vaccine was predicted using Protparam server. The results 146 revealed that this multi-epitope vaccine have low instability "as a value below 40" predicts that the 147 protein is stable. The IV1 construct showed the highest Isoelectric point with 8.52 value. From the 148 aliphatic Index of view, this construct showed aliphatic index more than 90 % ( We examined the numbers of primed CD4+ cells that produced IFN-γ in response to epitopes, using 160 ELISPOT assays described in results proposed that our multi-epitope vaccine was very stable with high aliphatic index and it was 184 potentially antigenic. As reported earlier, high aliphatic index shows the higher thermos-stability of the 185 constructed vaccine. At the present research, the aliphatic index was high, and instability was low and 186 Gravy indices were negative. Also, the higher PI, as the case of this study, shows the higher potential for 187 cell wall attachment. However, the proposed vaccine has high antigenicity. Authors declare no conflict of interest. 197 Acknowledgment We wish to thank the University of Isfahan for their supports. The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.10.985499 doi: bioRxiv preprint World Health Organization Novel coronavirus (2019-nCoV) situation reports HIV-1 gp120: A Target for Therapeutics and Vaccine 205 Design An overview of bioinformatics tools for 208 epitope prediction: implications on vaccine Development An overview of bioinformatics tools 211 for epitope prediction: implications on vaccine Development Adjuvanted multi-epitope vaccines protect HLA-A* 11: 214 01 transgenic mice against Toxoplasma gondii Immunogenicity of a multi-epitope dna vaccine encoding epitopes 216 from Cu-Zn superoxide dismutase and open reading Frames of Brucella abortus in mice In silico identification and validation of a 219 linear and naturally immunogenic B-cell epitope of the Plasmodium vivax malaria vaccine candidate 220 merozoite surface protein-9 Designing an efficient multi-epitope peptide vaccine against 223 Vibrio cholerae via combined immunoinformatics and protein interaction based approaches. 224 Computational Biology and Chemistry In silico design of a DNA based HIV-1 multi-epitope vaccine for 226 Chinese populations A novel multi-epitope vaccine for cross protection 229 against Hepatitis C Virus (HCV): an immunoinformatics